Sigma-Aldrich, Kings College London Ink Deal on miRNA Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma Life Science today announced a licensing deal with King's College London for the development and commercialization of technology to identify and validate miRNA targets in research and clinical diagnostics.

The technology was developed at the division of cancer studies at King's College. No further details about the technology or terms of the deal were disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece appearing in Newsday likens familial DNA search to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.

Startup companies are taking on personalized medicine, CNET reports.